技術轉移招商en文章 – Page 3 – 【國家衛生研究院】技轉及育成中心

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: a CXCR4-Targeted Antagonist”(2019/07/24)

技術轉移招商en文章, 技術轉移招商en文章, 產學研發徵求夥伴en文章 / 2019 年 7 月 24 日 2021 年 9 月 2 日

Title: NHRI technology, “DBPR807: a CXCR4-Targeted Antagonist” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description: DBPR807 is a potent antagonist targeting CXCR4 receptors for medical treatment of peripheral blood stem cell transplantation, hepatocellular carcinoma and acute myocardial infarction. Potential collaboration partner qualifications: be incorporated and approved by law and does not …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: a CXCR4-Targeted Antagonist”(2019/07/24) Read More »

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR215: A Stem Cell Mobilizer for Cell Based Therapy”(2019/07/24)

產學研發徵求夥伴en文章 / 2019 年 7 月 24 日 2021 年 9 月 2 日

Title: NHRI technology, “DBPR215: A Stem Cell Mobilizer for Cell Based Therapy” (abbreviated as “The Technology”) available for industry-academia collaboration technology licensing. Description: DBPR807 is a potent antagonist targeting CXCR4 receptors for medical treatment of peripheral blood stem cell transplantation, hepatocellular carcinoma and acute myocardial infarction. Potential collaboration partner qualifications: be incorporated and approved by …

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR215: A Stem Cell Mobilizer for Cell Based Therapy”(2019/07/24) Read More »